Hopp til innhold
NHI.no
Annonse

GIST: Forløp og prognose

Innhold i artikkelen

For ondartede svulster som ikke kan fjernes ved operasjon, er framtidsutsiktene ikke så gode. Overlevelsen er i snitt 60 måneder etter at man fikk påvist svulsten. Dersom svulsten lar seg fjerne, eller det viser seg at det er en godarted svulst, kan overlevelsen være svært god.

Dette dokumentet er basert på det profesjonelle dokumentet Gastrointestinale stromale tumorer . Referanselisten for dette dokumentet vises nedenfor

  1. Borregaard Larsen J. Imatinib - et gennembrud i behandlingen af gastrointestinale stromale tumorer (GIST). Ugeskr Læger 2003; 165: 3503-7. PubMed
  2. Zhao X, Yue C. Gastrointestinal stromal tumor. J Gastrointest Oncol. 2012 Sep. 3(3):189-208.
  3. Demeteri GD, Morgan J, Raut CP. Epidemiology, classification, clinical presentation, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST. UpToDate, last updated Oct 23, 2018. UpToDate
  4. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002; 10: 81. PubMed
  5. Huang HY, Li CF, Huang WW, et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 2007; 141: 748. Surgery
  6. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours. Ann Chir Gynaecol 1998;87:278-81. PubMed
  7. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2000;438:1-12. PubMed
  8. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Human Pathol 2000;32:578-82. PubMed
  9. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130(10):1466–78.
  10. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11:728-34. PubMed
  11. Kindblom LG, Remotti HE, Aldenborg F et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69. PubMed
  12. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80. PubMed
  13. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av sarkom, 2018. www.helsebiblioteket.no
  14. Chou FF, Eng HL, Sheen-Chen SM. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. Surgery 1996; 119: 171. Surgery
  15. Behazin NS. Gastrointestinal stromal tumors. Medscape, last updated Mar 30, 2015.
  16. Kamiyama Y, Aihara R, Nakabayashi T, et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005; 29: 1429. PubMed
  17. Morgan J, Raut CP. Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract. UpToDate, last updated Mar 26, 2018. UpToDate
  18. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3. PubMed
  19. Gronchi A, Raut CP. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. Ann Surg Oncol 2012; 19:1051. PubMed
Annonse
Annonse